[Form 4] Aura Biosciences, Inc. Insider Trading Activity

Rhea-AI Filing Summary

Aura Biosciences insider filing reports option exercises and a partial sale to cover costs. On 08/18/2025 Senior Vice President, Finance Amy Elazzouzi exercised long-held options to purchase 12,899 shares of Aura common stock across multiple option tranches and exercise prices. Of those shares, 7,722 were sold in multiple transactions at prices ranging from $6.57 to $6.80 (weighted average reported as $6.70). Following the transactions the reporting person beneficially owns 86,558 shares and holds no remaining derivative securities from the exercised options. The filing states the specific exercise prices and vesting/exercise dates for each option tranche.

Insights

Financial Analyst

TL;DR: Routine option exercise with partial sell-to-cover; limited market impact but increases insider equity stake.

The filing documents the exercise of 12,899 option shares by a senior finance officer, with 7,722 shares sold at prices between $6.57 and $6.80 to cover costs. The net result is a reported beneficial ownership of 86,558 shares. This is a common administration of long-held, vested options rather than an unexpected liquidity event. The granular exercise prices and expiration dates are disclosed, and all options reported as exercised were long-held and many are fully vested as noted.

Corporate Governance Expert

TL;DR: Disclosure is compliant and transparent; transactions appear consistent with typical executive option exercises.

The Form 4 provides required detail: transaction codes, exercise prices, number of shares acquired and sold, and post-transaction beneficial ownership. The seller provided a weighted average sale price and committed to furnish per-price breakdown on request, which supports transparency. No derivative holdings remain from these exercised options according to the filing, and the signature certifies the report.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Elazzouzi Amy

(Last) (First) (Middle)

C/O AURA BIOSCIENCES, INC.

80 GUEST STREET

(Street)

BOSTON MA 02135

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Aura Biosciences, Inc. [ AURA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Senior Vice President, Finance

3. Date of Earliest Transaction (Month/Day/Year)
08/18/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	08/18/2025		M(1)		2,554	A	$5.07	83,935	D
Common Stock	08/18/2025		M(1)		1,094	A	$5.48	85,029	D
Common Stock	08/18/2025		M(1)		547	A	$5.48	85,576	D
Common Stock	08/18/2025		M(1)		547	A	$5.21	86,123	D
Common Stock	08/18/2025		M(1)		4,744	A	$2.74	90,867	D
Common Stock	08/18/2025		M(1)		1,094	A	$3.16	91,961	D
Common Stock	08/18/2025		M(1)		2,319	A	$4.25	94,280	D
Common Stock	08/18/2025		S(1)		7,722	D	$6.7(2)	86,558	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$5.07	08/18/2025		M			2,554	(3)	09/03/2025	Common Stock	2,554	$0	0	D
Stock Option (Right to Buy)	$5.48	08/18/2025		M			1,094	(3)	04/11/2026	Common Stock	1,094	$0	0	D
Stock Option (Right to Buy)	$5.48	08/18/2025		M			547	(3)	10/26/2026	Common Stock	547	$0	0	D
Stock Option (Right to Buy)	$5.21	08/18/2025		M			547	(3)	04/12/2027	Common Stock	547	$0	0	D
Stock Option (Right to Buy)	$2.74	08/18/2025		M			4,744	(3)	02/21/2028	Common Stock	4,744	$0	0	D
Stock Option (Right to Buy)	$3.16	08/18/2025		M			1,094	(3)	02/06/2029	Common Stock	1,094	$0	0	D
Stock Option (Right to Buy)	$4.25	08/18/2025		M			2,319	(3)	03/16/2030	Common Stock	2,319	$0	0	D

Explanation of Responses:

1. On August 18, 2025, the Reporting Person exercised long held stock options to purchase 12,899 shares of the Issuer's common stock, 7,722 of which were sold to cover the exercise price of such options.

2. The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.57 to $6.80, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

3. This option is fully vested.

	/s/ Amy Elazzouzi	08/18/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.